{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T14:02:10Z","timestamp":1790431330841,"version":"4.1.0"},"reference-count":154,"publisher":"Bentham Science Publishers Ltd.","issue":"31","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2020,9,11]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Ranking above AIDS, Tuberculosis (TB) is the ninth leading cause of death affecting and\nkilling many individuals every year. Drugs\u2019 efficacy is limited by a series of problems such as Multi-\nDrug Resistance (MDR) and Extensively-Drug Resistance (XDR). Meanwhile, the only licensed vaccine\nBCG (Bacillus Calmette-Gu\u00e9rin) existing for over 90 years is not effective enough. Consequently,\nit is essential to develop novel vaccines for TB prevention and immunotherapy. This paper\nprovides an overall review of the TB prevalence, immune system response against TB and recent\nprogress of TB vaccine research and development. Several vaccines in clinical trials are described as\nwell as LAM-based candidates.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0929867326666181126112124","type":"journal-article","created":{"date-parts":[[2018,11,26]],"date-time":"2018-11-26T11:52:34Z","timestamp":1543233154000},"page":"5095-5118","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Novel Vaccine Candidates against Tuberculosis"],"prefix":"10.2174","volume":"27","author":[{"given":"Zhihao","family":"Li","sequence":"first","affiliation":[{"name":"Sorbonne Universite, CNRS, Institut Parisien de Chimie Moleculaire (UMR 8232), 4 Place Jussieu, 75005 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changping","family":"Zheng","sequence":"additional","affiliation":[{"name":"Sorbonne Universite, CNRS, Institut Parisien de Chimie Moleculaire (UMR 8232), 4 Place Jussieu, 75005 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Terreni","sequence":"additional","affiliation":[{"name":"Drug Sciences Department, University of Pavia, Viale Taramelli 12, 27100 Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Tanzi","sequence":"additional","affiliation":[{"name":"Drug Sciences Department, University of Pavia, Viale Taramelli 12, 27100 Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Sollogoub","sequence":"additional","affiliation":[{"name":"Sorbonne Universite, CNRS, Institut Parisien de Chimie Moleculaire (UMR 8232), 4 Place Jussieu, 75005 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongmin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Sorbonne Universite, CNRS, Institut Parisien de Chimie Moleculaire (UMR 8232), 4 Place Jussieu, 75005 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"4105","DOI":"10.1128\/IAI.00004-07","volume":"75(8)","author":"Radosevic,K.","year":"2007","unstructured":"Radosevic,K.; Wieland, C.W.; Rodriguez,A.; Weverling, G.J.; Mintardjo,R.; Gillissen,G.; Vogels,R.; Skeiky, Y.A.; Hone, D.M.; Sadoff, J.C.; van der Poll,T.; Havenga,M.; Goudsmit, J. Protective immune res ponses to a recombi-nant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon. Infect. Immun. 2007,75(8),4105-4115. http:\/\/dx.doi.org\/10.1128\/IAI.00004-07 PMID: 17526747","journal-title":"Infect.Immun"},{"key":"ref=2","unstructured":"World Health Organization. Global Tuberculosis Report. 2019. Available at: http:\/\/www.who.int\/tb\/publications\/ global_report\/ en\/"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1183\/09059180.00000511","volume":"20(120)","author":"Connell, D.W.","year":"2011","unstructured":"Connell, D.W.; Berry,M.; Cooke,G.; Kon, O.M. Update on tuberculosis: TB in the early 21 st century. Eur. Respir. Rev. 2011,20(120),71-84. http:\/\/dx.doi.org\/10.1183\/09059180.00000511 PMID: 21632795","journal-title":"Eur.Respir.Rev"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"5059","DOI":"10.1021\/ja057373q","volume":"128(15)","author":"Joe,M.","year":"2006","unstructured":"Joe,M.; Sun,D.; Taha,H.; Completo, G.C.; Croudace, J.E.; Lammas, D.A.; Besra, G.S.; Lowary, T.L. The 5-deoxy-5-methylthio-xylofuranose residue in mycobacterial lipoarabinomannan. Absolute stereochemistry, linkage po-sition, conformation and immunomodulatory activity, J. Am. Chem. Soc. 2006,128(15),5059-5072. http:\/\/dx.doi.org\/10.1021\/ja057373q PMID: 16608340","journal-title":"J.Am.Chem.Soc"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"10060","DOI":"10.1021\/acs.joc.5b01686","volume":"80(20)","author":"Wang,L.","year":"2015","unstructured":"Wang,L.; Feng,S.; An,L.; Gu,G.; Guo, Z. Synthetic and immunological studies of mycobacterial lipoarabinoman-nan oligosaccharides and their protein conjugates, J. Org. Chem. 2015,80(20),10060-10075. http:\/\/dx.doi.org\/10.1021\/acs.joc.5b01686 PMID: 26375482","journal-title":"Org.Chem"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/nrmicro1211","volume":"3(8)","author":"Andersen,P.","year":"2005","unstructured":"Andersen,P.; Doherty, T.M. The success and failure of BCG-implications for a novel tuberculosis vaccine. Nat. Rev. Microbiol. 2005,3(8),656-662. http:\/\/dx.doi.org\/10.1038\/nrmicro1211 PMID: 16012514","journal-title":"Nat.Rev.Microbiol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/S0140-6736(06) 68507-3","volume":"367(9517)","author":"Trunz, B.B.","year":"2006","unstructured":"Trunz, B.B.; Fine,P.; Dye, C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculo-sis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet. 2006,367(9517),1173-1180. http:\/\/dx.doi.org\/10.1016\/S0140-6736(06) 68507-3 PMID: 16616560","journal-title":"Lancet"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.tim.2008.07.007","volume":"16(10)","author":"K\u00e4llenius,G.","year":"2008","unstructured":"K\u00e4llenius,G.; Pawlowski,A.; Hamasur,B.; Svenson, S.B. Mycobacterial glycoconjugates as vaccine candidates against tuberculosis. Trends Microbiol. 2008,16(10),456-462. http:\/\/dx.doi.org\/10.1016\/j.tim.2008.07.007 PMID: 18774297","journal-title":"Trends Microbiol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1016\/S0140-6736(02) 08353-8","volume":"359(9315)","author":"Black, G.F.","year":"2002","unstructured":"Black, G.F.; Weir, R.E.; Floyd,S.; Bliss,L.; Warndorff, D.K.; Crampin, A.C.; Ngwira,B.; Sichali,L.; Nazareth,B.; Blackwell, J.M.; Branson,K.; Chaguluka, S.D.; D onovan,L.; Jarman,E.; King,E.; Fine, P.E.; Dockrell, H.M. BCG-induced increase in interferon-gamma response to myco-bacterial antigens and efficacy of BCG vaccination in Ma-lawi and the UK: two randomised controlled studies. Lan-cet. 2002,359(9315),1393-1401. http:\/\/dx.doi.org\/10.1016\/S0140-6736(02) 08353-8 PMID: 11978337","journal-title":"Lan-cet"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1086\/597069","volume":"199(6)","author":"Lalor, M.K.","year":"2009","unstructured":"Lalor, M.K.; Ben-Smith,A.; Gorak-Stolinska,P.; Weir, R.E.; Floyd,S.; Blitz,R.; Mvula,H.; Newport, M.J.; Bran-son,K.; McGrath,N.; Crampin, A.C.; Fine, P.E.; Dockrell, H.M. Population differences in immune responses to ba-cille calmette-gu\u00e9rin vaccination in infancy, J. Infect. Dis. 2009,199(6),795-800. http:\/\/dx.doi.org\/10.1086\/597069 PMID: 19434928","journal-title":"Infect.Dis"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1086\/597304","volume":"199(7)","author":"Mansoor,N.","year":"2009","unstructured":"Mansoor,N.; Scriba, T.J.; de Kock,M.; Tameris,M.; Abel,B.; Keyser,A.; Little,F.; Soares,A.; Gelderbloem,S.; Mlenjeni,S.; Denation,L.; Hawkridge,A.; Boom, W.H.; Kaplan,G.; Hussey, G.D.; Hanekom, W.A. HIV-1 infec-tion in infants severely impairs the immune response in-d uced by bacille calmette-gu\u00e9rin vaccine, J. Infect. Dis. 2009,199(7),982-990. http:\/\/dx.doi.org\/10.1086\/597304 PMID: 19236280","journal-title":"Infect.Dis"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1038\/79631","volume":"6(9)","author":"Kaufmann,S.H","year":"2000","unstructured":"Kaufmann.; S.H. Is the development of a new tuberculosis vaccine possible? Nat. Med. 2000,6(9),955-960. http:\/\/dx.doi.org\/10.1038\/79631 PMID: 10973302","journal-title":"Med"},{"key":"ref=13","first-page":"66","volume":"18(2)","author":"Govindarajan, K.K.","year":"2011","unstructured":"Govindarajan, K.K.; Chai, F.Y. BCG adenitis-need for increased awareness. Malays, J. Med. Sci. 2011,18(2),66-69. PMID: 22135589","journal-title":"Malays, J.Med..Sci"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/j.1365-2249.2009.03967.x","volume":"157(2)","author":"Abebe,F.","year":"2009","unstructured":"Abebe,F.; Bjune, G. The protective role of antibody re-sponses during Mycobacterium tuberculosis infection. Clin. Exp. Immunol. 2009,157(2),235-243. http:\/\/dx.doi.org\/10.1111\/j.1365-2249.2009.03967.x PMID: 19604263","journal-title":"Clin.Exp.Immunol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1111\/cmi.12480","volume":"17(9)","author":"Lerner, T.R.","year":"2015","unstructured":"Lerner, T.R.; Borel,S.; Gutierrez, M.G. The innate immune response in human tuberculosis. Cell. Microbiol. 2015,17(9),1277-1285. http:\/\/dx.doi.org\/10.1111\/cmi.12480 PMID: 26135005","journal-title":"Cell.Microbiol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"508.","DOI":"10.3389\/fimmu.2015.00508","volume":"6","author":"Allen,M.","year":"2015","unstructured":"Allen,M.; Bailey,C.; Cahatol,I.; Dodge,L.; Yim,J.; Kas-sissa,C.; Luong,J.; Kasko,S.; Pandya,S.; Venketaraman, V. Mechanisms of control of Mycobacterium tuberculosis by NK cells: role of glutathione. Front. Immunol. 2015,6,508. http:\/\/dx.doi.org\/10.3389\/fimmu.2015.00508 PMID: 26500648","journal-title":"Front.Immunol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1002\/eji.201343727","volume":"43(12)","author":"Cheng,Y.","year":"2013","unstructured":"Cheng,Y.; Schorey, J.S. Exosomes carrying mycobacterial antigens can protect mice against Mycobacterium tubercu-losis infection. Eur, J. Immunol. 2013,43(12),3279-3290. http:\/\/dx.doi.org\/10.1002\/eji.201343727 PMID: 23943377","journal-title":"Eur, J.Immunol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/S1473-3099(11) 70146-3","volume":"11(8)","author":"Kaufmann,S.H","year":"2011","unstructured":"Kaufmann.; S.H. Fact and fiction in tuberculosis vaccine research: 10 years later. Lancet Infect. Dis. 2011,11(8),633-640. http:\/\/dx.doi.org\/10.1016\/S1473-3099(11) 70146-3 PMID: 21798463","journal-title":"Lancet Infect.Dis"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1574-6968.2001.tb10575.x","volume":"197(1)","author":"Silva, C.L.","year":"2001","unstructured":"Silva, C.L.; Bonato, V.L.; Lima, K.M.; Coelho-Castelo, A.A.; Faccioli, L.H.; Sartori,A.; De Souza, A.O.; Le\u00e3o, S.C. Cytotoxic T cells and mycobacteria. FEMS Microbiol. Lett. 2001,197(1),11-18. http:\/\/dx.doi.org\/10.1111\/j.1574-6968.2001.tb10575.x PMID: 11287139","journal-title":"FEMS Microbiol.Lett"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/nm0307-299","volume":"13(3)","author":"Kaufmann, S.H.","year":"2007","unstructured":"Kaufmann, S.H.; Parida, S.K. Changing funding patterns in tuberculosis. Nat. Med. 2007,13(3),299-303. http:\/\/dx.doi.org\/10.1038\/nm0307-299 PMID: 17342144","journal-title":"Nat.Med"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1016\/S0140-6736(10) 60393-5","volume":"375(9731)","author":"Kaufmann, S.H.","year":"2010","unstructured":"Kaufmann, S.H.; Hussey,G.; Lambert, P.H. New vaccines for tuberculosis. Lancet. 2010,375(9731),2110-2119. http:\/\/dx.doi.org\/10.1016\/S0140-6736(10) 60393-5 PMID: 20488515","journal-title":"Lancet"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.immuni.2010.09.015","volume":"33(4)","author":"Kaufmann,S.H","year":"2010","unstructured":"Kaufmann.; S.H. Future vaccination strategies against tu-berculosis: thinking outside the box. Immunity. 2010,33(4),567-577. http:\/\/dx.doi.org\/10.1016\/j.immuni.2010.09.015 PMID: 21029966","journal-title":"Immunity"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1128\/CMR.15.2.294-309.2002","volume":"15(2)","author":"van Crevel,R.","year":"2002","unstructured":"van Crevel,R.; Ottenhoff, T.H.; van der Meer, J.W. Innate immunity to Mycobacterium tuberculosis Clin. Microbiol. Rev. 2002,15(2),294-309. http:\/\/dx.doi.org\/10.1128\/CMR.15.2.294-309.2002 PMID: 11932234","journal-title":"Microbiol.Rev"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41577-018-0028-0","volume":"18(9)","author":"Li,H.","year":"2018","unstructured":"Li,H.; Javid, B. Antibodies and tuberculosis: finally com-ing of age? Nat. Rev. Immunol. 2018,18(9),591-596. http:\/\/dx.doi.org\/10.1038\/s41577-018-0028-0 PMID: 29872 140","journal-title":"Rev.Immunol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/icb.2009.14","volume":"87(4)","author":"Aagaard,C.","year":"2009","unstructured":"Aagaard,C.; Dietrich,J.; Doherty,M.; Andersen, P. TB vaccines: current status and future perspectives. Immunol. Cell Biol. 2009,87(4),279-286. http:\/\/dx.doi.org\/10.1038\/icb.2009.14 PMID: 19350048","journal-title":"Immunol.Cell Biol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1128\/CMR.18.4.687-702.2005","volume":"18(4)","author":"Doherty, T.M.","year":"2005","unstructured":"Doherty, T.M.; Andersen, P. Vaccines for tuberculosis: novel concepts and recent progress. Clin. Microbiol. Rev. 2005,18(4),687-702. http:\/\/dx.doi.org\/10.1128\/CMR.18.4.687-702.2005 PMID: 16223953","journal-title":"Clin.Microbiol.Rev"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.2174\/1385272819666150810204736","volume":"20(11)","author":"Bavaro,T.","year":"2016","unstructured":"Bavaro,T.; Piubelli,L.; Amicosante,M.; Terreni, M. From new diagnostic targets to recombinant proteins and semi-synthetic protein-based vaccines. Curr. Org. Synth. 2016,20(11),1150-1168. https:\/\/dx.doi.org\/10.2174\/1385272819666150810204736","journal-title":"Curr.Org.Synth"},{"key":"ref=28","author":"Bekmurzayeva,A.","unstructured":"Bekmurzayeva,A.; Sypabekova,M.; Kanayeva, D. Tuber-culosis diagnosis using immunodominant, secreted antigens of Mycobacterium tuberculosis Tuberculosis (Edinb.),2013,93(4),381-388. http:\/\/dx.doi.org\/10.1016\/j.tube.2013.03.003 PMID: 23602700"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"321.","DOI":"10.3389\/fimmu.2014.00321","volume":"5","author":"Huygen,K","year":"2014","unstructured":"Huygen.; K. The immunodominant T-cell epitopes of the mycolyl-transferases of the antigen 85 complex of M. tu-berculosis Front. Immunol. 2014,5,321. http:\/\/dx.doi.org\/10.3389\/fimmu.2014.00321 PMID: 25071781","journal-title":"tu-berculosis Front.Immunol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1046\/j.1365-2567.1998.00449.x","volume":"93(3)","author":"Lightbody, K.A.","year":"1998","unstructured":"Lightbody, K.A.; Girvin, R.M.; Pollock, D.A.; Mackie, D.P.; Neill, S.D.; Pollock, J.M. Recognition of a common mycobacterial T-cell epitope in MPB59 of Mycobacterium bovis. Immunology. 1998,93(3),314-322. http:\/\/dx.doi.org\/10.1046\/j.1365-2567.1998.00449.x PMID: 9640240","journal-title":"Immunology"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1128\/IAI.68.7.3933-3940.2000","volume":"68(7)","author":"Mustafa, A.S.","year":"2000","unstructured":"Mustafa, A.S.; Shaban, F.A.; Abal, A.T.; Al-Attiyah,R.; Wiker, H.G.; Lundin, K.E.; Oftung,F.; Huygen, K. Identi-fication and HLA restriction of naturally derived Th1-cell epitopes from the secreted Mycobacterium tuberculosis an-tigen 85B recognized by antigen-specific human CD4(+)  T-cell lines. Infect. Immun. 2000,68(7),3933-3940. http:\/\/dx.doi.org\/10.1128\/IAI.68.7.3933-3940.2000 PMID: 10858206","journal-title":"Infect.Immun"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1046\/j.1365-2249.2001.01450.x","volume":"123(2)","author":"Valle, M.T.","year":"2001","unstructured":"Valle, M.T.; Megiovanni, A.M.; Merlo,A.; Li Pira,G.; Bottone,L.; Angelini,G.; Bracci,L.; Lozzi,L.; Huygen,K.; Manca, F. Epitope focus, clonal composition and Th1 phenotype of the human CD4 response to the secretory my-cobacterial antigen Ag85. Clin. Exp. Immunol. 2001,123(2),226-232. ht tp:\/\/dx.doi.org\/10.1046\/j.1365-2249.2001.01450.x PMID: 11207652","journal-title":"Clin.Exp.Immunol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ijmyco.2015.09.006","volume":"5(1)","author":"Kadir, N.A.","year":"2016","unstructured":"Kadir, N.A.; Sarmiento, M.E.; Acosta,A.; Norazmi, M-N. Cellular and humoral immunogenicity of recombinant My-cobacterium smegmatis expressing Ag85B epitopes in mice. Int, J. Mycobacteriol. 2016,5(1),7-13. http:\/\/dx.doi.org\/10.1016\/j.ijmyco.2015.09.006 PMID: 26927984","journal-title":"Int, J.Mycobacteriol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1128\/IAI.68.1.214-220.2000","volume":"68(1)","author":"Skj\u00f8t, R.L.V.","year":"2000","unstructured":"Skj\u00f8t, R.L.V.; Oettinger,T.; Rosenkrands,I.; Ravn,P.; Brock,I.; Jacobsen,S.; Andersen, P. Comparative evalua-tion of low-molecular-mass proteins from Mycobacterium tuberculosis identifies members of the ESAT-6 family as immunodominant T-cell antigens. Infect. Immun. 2000,68(1),214-220. http:\/\/dx.doi.org\/10.1128\/IAI.68.1.214-220.2000 PMID: 10603390","journal-title":"Infect.Immun"},{"key":"ref=35","first-page":"3527","volume":"157(8)","author":"Brandt,L.","year":"1996","unstructured":"Brandt,L.; Oettinger,T.; Holm,A.; Andersen, A.B.; An-dersen, P. Key epitopes on the ESAT-6 antigen recognized in mice during the recall of protective immunity to Myco-bacterium tuberculosis J. Immunol. 1996,157(8),3527-3533. PMID: 8871652","journal-title":"Immunol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1128\/IAI.66.2.717-723.1998","volume":"66(2)","author":"Harboe,M.","year":"1998","unstructured":"Harboe,M.; Malin, A.S.; Dockrell, H.S.; Wiker, H.G.; Ulvund,G.; Holm,A.; J\u00f8rgensen, M.C.; Andersen, P. B-cell epitopes and quantification of the ESAT-6 protein of Mycobacterium tuberculosis Infect. Immun. 1998,66(2),717-723. http:\/\/dx.doi.org\/10.1128\/IAI.66.2.717-723.1998 PMID: 9453632","journal-title":"Immun"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.chroma.2014.09.041","volume":"1367","author":"Temporini,C.","year":"2014","unstructured":"Temporini,C.; Bavaro,T.; Tengattini,S.; Serra,I.; Mar-rubini,G.; Calleri,E.; Fasanella,F.; Piubelli,L.; Marinelli,F.; Pollegioni,L.; Speranza,G.; Massolini,G.; Terreni, M. Liquid chromatography-mass spectrometry structural char-acterization of neo glycoproteins aiding the rational design and synthesis of a novel glycovaccine for protection against tuberculosis, J. Chromatogr. A. 2014,1367,57-67. http:\/\/dx.doi.org\/10.1016\/j.chroma.2014.09.041 PMID: 25282312","journal-title":"Chromatogr.A"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"e82196.","DOI":"10.1371\/journal.pone.0082196","volume":"8(12)","author":"Li,L.","year":"2013","unstructured":"Li,L.; Yang,B.; Yu,S.; Zhang,X.; Lao,S.; Wu, C. Human CD8+ T cells from TB pleurisy respond to four immuno-dominant epitopes in Mtb CFP10 restricted by HLA-B al-leles. PLoS One. 2013,8(12),e82196. http:\/\/dx.doi.org\/10.1371\/journal.pone.0082196 PMID: 24349220","journal-title":"PLoS One"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1046\/j.1365-3083.1996.d01-260.x","volume":"43(6)","author":"Roche, P.W.","year":"1996","unstructured":"Roche, P.W.; Feng, C.G.; Britton, W.J. Human T-cell epi-topes on the Mycobacterium tuberculosis secreted protein MPT64. Scand, J. Immunol. 1996,43(6),662-670. http:\/\/dx.doi.org\/10.1046\/j.1365-3083.1996.d01-260.x PMID: 8658056","journal-title":"Scand, J.Immunol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1128\/IAI.62.5.2058-2064.1994","volume":"62(5)","author":"Oettinger,T.","year":"1994","unstructured":"Oettinger,T.; Andersen, A.B. Cloning and B-cell-epitope mapping of MPT64 from Mycobacterium tuberculosis H37Rv. Infect. Immun. 1994,62(5),2058-2064. http:\/\/dx.doi.org\/10.1128\/IAI.62.5.2058-2064.1994 PMID: 7513311","journal-title":"Infect.Immun"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1159\/000316375","volume":"19(5)","author":"Mustafa,A.S","year":"2010","unstructured":"Mustafa.; A.S. In silico binding predictions for identifica-tion of HLA-DR-promiscuous regions and epitopes of My-cobacterium tuberculosis protein MPT64 (Rv1980c)  and their recognition by human Th1 cells. Med. Princ. Pract. 2010,19(5),367-372. http:\/\/dx.doi.org\/10.1159\/000316375 PMID: 20639660","journal-title":"Med.Princ.Pract"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"7948","DOI":"10.4049\/jimm unol.181.11.7948","volume":"181(11)","author":"Bertholet,S.","year":"2008","unstructured":"Bertholet,S.; Ireton, G.C.; Kahn,M.; Guderian,J.; Moha-math,R.; Stride,N.; Laughlin, E.M.; Baldwin, S.L.; Ved-vick, T.S.; Coler, R.N.; Reed, S.G. Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis J. Immunol. 2008,181(11),7948-7957. http:\/\/dx.doi.org\/10.4049\/jimm unol.181.11.7948 PMID: 19017986","journal-title":"Immunol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/nature05580","volume":"445(7129)","author":"Zhou,T.","year":"2007","unstructured":"Zhou,T.; Xu,L.; Dey,B.; Hessell, A.J.; Van Ryk,D.; Xiang, S.H.; Yang,X.; Zhang, M.Y.; Zwick, M.B.; Arthos,J.; Burton, D.R.; Dimitrov, D.S.; Sodroski,J.; Wyatt,R.; Nabel, G.J.; Kwong, P.D. Structural definition of a con-served neutralization epitope on HIV-1 gp120. Nature. 2007,445(7129),732-737. http:\/\/dx.doi.org\/10.1038\/nature05580 PMID: 17301785","journal-title":"Nature"},{"key":"ref=44","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.250480397","author":"Horwitz, M.A.","unstructured":"Horwitz, M.A.; Harth,G.; Dillon, B.J.; Masle\u0161a-Galic\u2019, S. Recombinant bacillus calmette-guerin (BCG)  vaccines ex-pressing the Mycobacterium tuberculosis 30-kDa major se-cretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc. Natl. Acad. Sci. USA. 2000,97(25),13853-13858. http:\/\/dx.doi.org\/10.1073\/pnas.250480397 PMID: 11095745 [ 45] Orme, I.M. Tuberculosis vaccine types and timings. Clin. Vaccine Immunol. 2015,22(3),249-257. http:\/\/dx.doi.org\/10.1128\/CVI.00718-14 PMID: 25540272","journal-title":"Proc.Natl.Acad.Sci.USA"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.1172\/JCI24617","volume":"115(9)","author":"Grode,L.","year":"2005","unstructured":"Grode,L.; Seiler,P.; Baumann,S.; Hess,J.; Brinkmann,V.; Nasser Eddine,A.; Mann,P.; Goosmann,C.; Bander-mann,S.; Smith,D.; Bancroft, G.J.; Reyrat, J.M.; van Sool-ingen,D.; Raupach,B.; Kaufmann, S.H. Increased vaccine efficacy against tuberculosis of recombinant Mycobacte-rium bovis bacille calmette-gu\u00e9rin mutants that secrete lis-teriolysin, J. Clin. Invest. 2005,115(9),2472-2479. http:\/\/dx.doi.org\/10.1172\/JCI24617 PMID: 16110326","journal-title":"Clin.Invest"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1016\/j.vaccine.2012.12.053","volume":"31(9)","author":"Grode,L.","year":"2013","unstructured":"Grode,L.; Ganoza, C.A.; Brohm,C.; Weiner, J. III.; Eisele,B.; Kaufmann, S.H. Safety and immunogenicity of the re-combinant BCG vaccine VPM1002 in a phase 1 open-label randomized clinical trial. Vaccine. 2013,31(9),1340-1348. http:\/\/dx.doi.org\/10.1016\/j.vaccine.2012.12.053 PMID: 23290835","journal-title":"Vaccine"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1093\/infdis\/jiu675","volume":"211(11)","author":"Saiga,H.","year":"2015","unstructured":"Saiga,H.; Nieuwenhuizen,N.; Gengenbacher,M.; Koehler, A.B.; Schuerer,S.; Moura-Alves,P.; Wagner,I.; Mol-lenkopf, H.J.; Dorhoi,A.; Kaufmann, S.H. The Recombi-nant BCG ? ureC: HLY vaccine targets the AIM2 inflam-masome to induce autophagy and inflammation, J. Infect. Dis. 2015,211(11),1831-1841. http:\/\/dx.doi.org\/10.1093\/infdis\/jiu675 PMID: 25505299","journal-title":"Infect.Dis"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1586\/14760584.2014.905746","volume":"13(5)","author":"Kaufmann, S.H.","year":"2014","unstructured":"Kaufmann, S.H.; Cotton, M.F.; Eisele,B.; Gengenbacher,M.; Grode,L.; Hesseling, A.C.; Walzl, G. The BCG re-placement vaccine VPM1002: from drawing board to clini-cal trial. Expert Rev. Vaccines. 2014,13(5),619-630. http:\/\/dx.doi.org\/10.1586\/14760584.2014.905746 PMID: 24702486","journal-title":"Expert Rev.Vaccines"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"e00439","DOI":"10.1128\/CVI.00439-16","volume":"24(2)","author":"Loxton, A.G.","year":"2017","unstructured":"Loxton, A.G.; Knaul, J.K.; Grode,L.; Gutschmidt,A.; Meller,C.; Eisele,B.; Johnstone,H.; van der Spuy,G.; Maertzdorf,J.; Kaufmann, S.H.E.; Hesseling, A.C.; Walzl,G.; Cotton, M.F. Safety and immunogenicity of the recom-binant Mycobacterium bovis BCG vaccine VPM1002 in HIV-unexposed newborn infants in South Africa. Clin. Vaccine Immunol. 2017,24(2),e00439-e00416. http:\/\/dx.doi.org\/10.1128\/CVI.00439-16 PMID: 27974398","journal-title":"Clin.Vaccine Immunol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1093\/infdis\/jir592","volume":"204(10)","author":"Desel,C.","year":"2011","unstructured":"Desel,C.; Dorhoi,A.; Bandermann,S.; Grode,L.; Eisele,B.; Kaufmann, S.H.; Recombinant, B.C.G. Recombinant BCG ?ureC HLY+ induces superior protection over paren-tal BCG by stimulating a balanced combination of type 1 and type 17 cytokine responses, J. Infect. Dis. 2011,204(10),1573-1584. http:\/\/dx.doi.org\/10.1093\/infdis\/jir592 PMID: 21933877","journal-title":"Infect.Dis"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"4709","DOI":"10.1016\/j.vaccine.2009.05.050","volume":"27(34)","author":"Larsen, M.H.","year":"2009","unstructured":"Larsen, M.H.; Biermann,K.; Chen,B.; Hsu,T.; Samban-damurthy, V.K.; Lackner, A.A.; Aye, P.P.; Didier,P.; Huang,D.; Shao,L.; Wei,H.; Letvin, N.L.; Frothingham,R.; Haynes, B.F.; Chen, Z.W.; Jacobs, W.R.Jr. Efficacy and safety of live attenuated persistent and rapidly cleared Mycobacterium tuberculosis vaccine candidates in non-human primates. Vaccine. 2009,27(34),4709-4717. http:\/\/dx.doi.org\/10.1016\/j.vaccine.2009.05.050 PMID: 19500524","journal-title":"Vaccine"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"4867","DOI":"10.1016\/j.vaccine.2013.07.051","volume":"31(42)","author":"Arbues,A.","year":"2013","unstructured":"Arbues,A.; Aguilo, J.I.; Gonzalo-Asensio,J.; Marinova,D.; Uranga,S.; Puentes,E.; Fernandez,C.; Parra,A.; Car-dona, P.J.; Vilaplana,C.; Ausina,V.; Williams,A.; Clark,S.; Malaga,W.; Guilhot,C.; Gicquel,B.; Martin, C. Con-struction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-b ased vaccine to enter clinical trials. Vaccine. 2013,31(42),4867-4873. http:\/\/dx.doi.org\/10.1016\/j.vaccine.2013.07.051 PMID: 23965219","journal-title":"Vaccine"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"1803.","DOI":"10.3389\/fimmu.2017.01803","volume":"8","author":"Gonzalo-Asensio,J.","year":"2017","unstructured":"Gonzalo-Asensio,J.; Marinova,D.; Martin,C.; Aguilo, N. MTBVAC: Attenuating the human pathogen of Tuberculo-sis (TB)  toward a promising vaccine against the TB epi-demic. Front. Immunol. 2017,8,1803. http:\/\/dx.doi.org\/10.3389\/fimmu.2017.01803 PMID: 29326700","journal-title":"Front.Immunol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1038\/ng.3704","volume":"48(12)","author":"Stucki,D.","year":"2016","unstructured":"Stucki,D.; Brites,D.; Jeljeli,L.; Coscolla,M.; Liu,Q.; Trauner,A.; Fenner,L.; Rutaihwa,L.; Borrell,S.; Luo,T.; Gao,Q.; Kato-Maeda,M.; Ballif,M.; Egger,M.; Macedo,R.; Mardassi,H.; Moreno,M.; Tudo Vilanova,G.; Fyfe,J.; Globan,M.; Thomas,J.; Jamieson,F.; Guthrie, J.L.; As-ante-Poku,A.; Yeboah-Manu,D.; Wampande,E.; Ssen-gooba,W.; Joloba,M.; Henry Boom,W.; Basu,I.; Bower,J.; Saraiva,M.; Vaconcellos, S.E.G.; Suffys,P.; Koch,A.; Wilkinson,R.; Gail-Bekker,L.; Malla,B.; Ley, S.D.; Beck, H.P.; de Jong, B.C.; To-it,K.; Sanchez-Padilla,E.; Bonnet,M.; Gil-Brusola,A.; Frank,M.; Penlap Beng, V.N.; Eisen-ach,K.; Alani,I.; Wangui Ndung\u2019u,P.; Revathi,G.; Gehre,F.; Akter,S.; Ntoumi,F.; Stewart-Isherwood,L.; Ntinginya, N.E.; Rachow,A.; Hoelscher,M.; Cirillo, D.M.; Skenders,G.; Hoffner,S.; Bakonyte,D.; Stakenas,P.; Diel,R.; Crudu,V.; Moldovan,O.; Al-Hajoj,S.; Otero,L.; Bar-letta,F.; Jane Carter,E.; Diero,L.; Supply,P.; Comas,I.; Niemann,S.; Gagneux, S. Mycobacterium tuberculosis lineage 4 comprises globally distributed and geographically restricted sublineages. Nat. Genet. 2016,48(12),1535-1543. http:\/\/dx.doi.org\/10.1038\/ng.3704 PMID: 27798628","journal-title":"Nat.Genet"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"3408","DOI":"10.1016\/j.vaccine.2006.03.017","volume":"24(17)","author":"Martin,C.","year":"2006","unstructured":"Martin,C.; Williams,A.; Hernandez-Pando,R.; Cardona, P.J.; Gormley,E.; Bordat,Y.; Soto, C.Y.; Clark, S.O.; Hatch, G.J.; Aguilar,D.; Ausina,V.; Gicquel, B. The live Mycobacterium tuberculosis phoP mutant strain is more at-tenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs. Vaccine. 2006,24(17),3408-3419. http:\/\/dx.doi.org\/10.1016\/j.vaccine.2006.03.017 PMID: 16564606","journal-title":"Vaccine"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"16085.","DOI":"10.1038\/ncomms16085","volume":"8","author":"Aguilo,N.","year":"2017","unstructured":"Aguilo,N.; Gonzalo-Asensio,J.; Alvarez-Arguedas,S.; Marinova,D.; Gomez, A.B.; Uranga,S.; Spallek,R.; Singh,M.; Audran,R.; Spertini,F.; Martin, C. Reacto-genicity to major tuberculosis antigens absent in BCG is linked to improved protection against Mycobacterium tu-berculosis Nat. Commun. 2017,8,16085. http:\/\/dx.doi.org\/10.1038\/ncomms16085 PMID: 28706226","journal-title":"Commun"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1093\/infdis\/jix030","volume":"216(5)","author":"Clark,S.","year":"2017","unstructured":"Clark,S.; Lanni,F.; Marinova,D.; Rayner,E.; Martin,C.; Williams, A. Revaccination of guinea pigs with the live at-tenuated Mycobacterium tuberculosis vaccine MTBVAC improves BCG\u2019s protection against tuberculosis, J. Infect. Dis. 2017,216(5),525-533. http:\/\/dx.doi.org\/10.1093\/infdis\/jix030 PMID: 28329234","journal-title":"Infect.Dis"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1128\/IAI.73.2.1196-1203.2005","volume":"73(2)","author":"Sambandamurthy, V.K.","year":"2005","unstructured":"Sambandamurthy, V.K.; Derrick, S.C.; Jalapathy, K.V.; Chen,B.; Russell, R.G.; Morris, S.L.; Jacobs, W.R.Jr. Long-term protection against tuberculosis following vacci-nation with a severely attenuated double lysine and pan-tothenate auxotroph of Mycobacterium tuberculosis Infect. Immun. 2005,73(2),1196-1203. http:\/\/dx.doi.org\/10.1128\/IAI.73.2.1196-1203.2005 PMID: 15664964","journal-title":"Immun"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"6309","DOI":"10.1016\/j.vaccine.2006.05.097","volume":"24(37-39)","author":"Sambandamurthy, V.K.","year":"2006","unstructured":"Sambandamurthy, V.K.; Derrick, S.C.; Hsu,T.; Chen,B.; Larsen, M.H.; Jalapathy, K.V.; Chen,M.; Kim,J.; Porcelli, S.A.; Chan,J.; Morris, S.L.; Jacobs, W.R.Jr. Mycobacte-rium tuberculosis DeltaRD1 DeltapanCD: a safe and lim-ited replicating mutant strain that protects immunocompe-tent and immunocompromised mice against experimental tuberculosis. Vaccine. 2006,24(37-39),6309-6320. http:\/\/dx.doi.org\/10.1016\/j.vaccine.2006.05.097 PMID: 16860907","journal-title":"Vaccine"},{"key":"ref=61","author":"Tang,J.","unstructured":"Tang,J.; Yam, W.C.; Chen, Z. Mycobacterium tuberculosis infection and vaccine development. Tuberculosis (Edinb.),2016,98,30-41. ht tp:\/\/dx.doi.org\/10.1016\/j.tube.2016.02.005 PMID: 27156616","journal-title":"Tuberculosis (Edinb."},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"a018523.","DOI":"10.1101\/cshperspect.a018523","volume":"4(6)","author":"Andersen,P.","year":"2014","unstructured":"Andersen,P.; Kaufmann, S.H. Novel vaccination strategies against tuberculosis. Cold Spring Harb. Perspect. Med. 2014,4(6),a018523. http:\/\/dx.doi.org\/10.1101\/cshperspect.a018523 PMID: 24890836","journal-title":"Cold Spring Harb.Perspect.Med"},{"key":"ref=63","first-page":"3359","volume":"154(7)","author":"Andersen,P.","year":"1995","unstructured":"Andersen,P.; Andersen, A.B.; S\u00f8rensen, A.L.; Nagai, S. Recall of long-lived immunity to Mycobacterium tubercu-losis infection in mice, J. Immunol. 1995,154(7),3359-3372. PMID: 7897219","journal-title":"Immunol"},{"key":"ref=64","author":"van Dissel, J.T.","unstructured":"van Dissel, J.T.; Arend, S.M.; Prins,C.; Bang,P.; Ting-skov, P.N.; Lingnau,K.; Nouta,J.; Klein, M.R.; Rosenk-rands,I.; Ottenhoff, T.H.; Kromann,I.; Doherty, T.M.; An-dersen, P. Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in na\u00efve human. unteers. Vaccine. 2010,28(20),3571-3581. http:\/\/dx.doi.org\/10.1016\/j.vaccine.2010.02.094 PMID: 20226890","journal-title":"unteers"},{"key":"ref=65","author":"van Dissel, J.T.","unstructured":"van Dissel, J.T.; Soonawala,D.; Joosten, S.A.; Prins,C.; Arend, S.M.; Bang,P.; Tingskov, P.N.; Lingnau,K.; Nouta,J.; Hoff, S.T.; Rosenkrands,I.; Kromann,I.; Otten-hoff, T.H.; Doherty, T.M.; Andersen, P. Ag85B-ESAT-6 adjuvanted with IC31\u00ae promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in. unteers with previous BCG vaccination or tuberculosis infection. Vaccine. 2011,29(11),2100-2109. http:\/\/dx.doi.org\/10.1016\/j.vaccine.2010.12.135 PMID: 21256189"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.4161\/hv.6.12.13143","volume":"6(12)","author":"Ottenhoff, T.H.","year":"2010","unstructured":"Ottenhoff, T.H.; Doherty, T.M.; van Dissel, J.T.; Bang,P.; Lingnau,K.; Kromann,I.; Andersen, P. First in humans: a new molecularly defined vaccine shows excellent safety and strong induction of long-lived Mycobacterium tubercu-losis-specific Th1-cell like responses. Hum. Vaccin. 2010,6(12),1007-1015. http:\/\/dx.doi.org\/10.4161\/hv.6.12.13143 PMID: 21178394","journal-title":"Hum.Vaccin"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1080\/21645515.2018.1458806","volume":"14(7)","author":"Gong,W.","year":"2018","unstructured":"Gong,W.; Liang,Y.; Wu, X. The current status, chal-lenges, and future developments of new tuberculosis vac-cines. Hum. Vaccin. Immunother. 2018,14(7),1697-1716. http:\/\/dx.doi.org\/10.1080\/21645515.2018.1458806 PMID: 29601253","journal-title":"Hum.Vaccin.Immunother"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.vaccine.2009.10.114","volume":"28(4)","author":"Skeiky, Y.A.","year":"2010","unstructured":"Skeiky, Y.A.; Dietrich,J.; Lasco, T.M.; Stagliano,K.; Dheenadhayalan,V.; Goetz, M.A.; Cantarero,L.; Basaraba, R.J.; Bang,P.; Kromann,I.; McMclain, J.B.; Sadoff, J.C.; Andersen, P. Non-clinical efficacy and safety of Hy-Vac4:IC31 vaccine administered in a BCG prime-boost regimen. Vaccine. 2010,28(4),1084-1093. http:\/\/dx.doi.org\/10.1016\/j.vaccine.2009.10.114 PMID: 19896449","journal-title":"Vaccine"},{"key":"ref=69","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2007.03.004","author":"Andersen,P.","unstructured":"Andersen,P.; Doherty, T.M.; Pai,M.; Weldingh, K. The prognosis of latent tuberculosis: can disease be pre-dicted? Trends Mol. Med. 2007,13( 5),175-182. https:\/\/dx.doi.org\/10.1016\/j.molmed.2007.03.004 PMID.; 17418641","journal-title":"Med"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/j.vaccine.2017.01.055","volume":"35(12)","author":"Norrby,M.","year":"2017","unstructured":"Norrby,M.; Vesikari,T.; Lindqvist,L.; Maeurer,M.; Ah-med,R.; Mahdavifar,S.; Bennett,S.; McClain, J.B.; Shep-herd, B.M.; Li,D.; Hokey, D.A.; Kromann,I.; Hoff, S.T.; Andersen,P.; de Visser, A.W.; Joosten, S.A.; Ottenhoff, T.H.M.; Andersson,J.; Brighenti, S. Safety and immuno-genicity of the novel H4:IC31 tuberculosis vaccine candi-date in BCG-vaccinated adults: two phase I dose escalation trials. Vaccine. 2017,35(12),1652-1661. http:\/\/dx.doi.org\/10.1016\/j.vaccine.2017.01.055 PMID: 28216183","journal-title":"Vaccine"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"475","DOI":"10.4161\/hv.8570","volume":"5(7)","author":"Von,Eschen,K.","year":"2009","unstructured":"Von Eschen,K.; Morrison,R.; Braun,M.; Ofori-Anyinam,O.; De Kock,E.; Pavithran,P.; Koutsoukos,M.; Moris,P.; Cain,D.; Dubois, M-C.; Cohen,J.; Ballou, W.R. The can-didate tuberculosis vaccine Mtb72F\/AS02a: tolerability and immunogenicity in humans. Hum. Vaccin. 2009,5(7),475-482. http:\/\/dx.doi.org\/10.4161\/hv.8570 PMID: 19587528","journal-title":"Hum.Vaccin"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1073\/pnas.0712077106","volume":"106(7)","author":"Reed, S.G.","year":"2009","unstructured":"Reed, S.G.; Coler, R.N.; Dalemans,W.; Tan, E.V.; DeLa Cruz, E.C.; Basaraba, R.J.; Orme, I.M.; Skeiky, Y.A.; Al-derson, M.R.; Cowgill, K.D.; Prieels, J.P.; Abalos, R.M.; Dubois, M.C.; Cohen,J.; Mettens,P.; Lobet, Y. Defined tuberculosis vaccine, Mtb72F\/AS02A, evidence of protec-tion in cynomolgus monkeys. Proc. Natl. Acad. Sci. USA. 2009,106(7),2301-2306. http:\/\/dx.doi.org\/10.1073\/pnas.0712077106 PMID: 19188599","journal-title":"Proc.Natl.Acad.Sci.USA"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1128\/IAI.74.4.2392-2401.2006","volume":"74(4)","author":"Tsenova,L.","year":"2006","unstructured":"Tsenova,L.; Harbacheuski,R.; Moreira, A.L.; Ellison,E.; Dalemans,W.; Alderson, M.R.; Mathema,B.; Reed, S.G.; Skeiky, Y.A.; Kaplan, G. Evaluation of the Mtb72F poly-protein vaccine in a rabbit model of tuberculous meningitis. Infect. Immun. 2006,74(4),2392-2401. http:\/\/dx.doi.org\/10.1128\/IAI.74.4.2392-2401.2006 PMID: 16552069","journal-title":"Infect.Immun"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"6622","DOI":"10.1128\/IAI.72.11.6622-6632.2004","volume":"72(11)","author":"Brandt,L.","year":"2004","unstructured":"Brandt,L.; Skeiky, Y.A.; Alderson, M.R.; Lobet,Y.; Dalemans,W.; Turner, O.C.; Basaraba, R.J.; Izzo, A.A.; Lasco, T.M.; Chapman, P.L.; Reed, S.G.; Orme, I.M. The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs. Infect. Immun. 2004,72(11),6622-6632. http:\/\/dx.doi.org\/10.1128\/IAI.72.11.6622-6632.2004 PMID: 15501795","journal-title":"tuberculosis-infected guinea pigs.Infect.Immun"},{"key":"ref=75","author":"Spertini,F.","unstructured":"Spertini,F.; Audran,R.; Lurati,F.; Ofori-Anyinam,O.; Zysset,F.; Vandepapeli\u00e8re,P.; Moris,P.; Demoiti\u00e9, M.A.; Mettens,P.; Vinals,C.; Vastiau,I.; Jongert,E.; Cohen,J.; Ballou, W.R. The candidate tuberculosis vaccine Mtb72F\/AS02 in PPD pos itive adults: a ra ndomized con-trolled phase I\/II study. Tuberculosis (Edinb.),2013,93(2),179-188. http:\/\/dx.doi.org\/10.1016\/j.tube.2012.10.011 PMID: 23219236","journal-title":"Tuberculosis (Edinb.)"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1016\/j.vaccine.2012.05.035","volume":"31(17)","author":"Leroux-Roels,I.","year":"2013","unstructured":"Leroux-Roels,I.; Forgus,S.; De Boever,F.; Clement,F.; Demoiti\u00e9, M.A.; Mettens,P.; Moris,P.; Ledent,E.; Leroux-Roels,G.; Ofori-Anyinam, O. M72 Study Group. Improved CD4 ? T cell responses to Mycobacterium tuber-culosis in PPD-negative adults by M72\/AS01 as compared to the M72\/AS02 and Mtb72F\/AS02 tuberculosis candidate vaccine formulations: a randomized trial. Vaccine. 2013,31(17),2196-2206. http:\/\/dx.doi.org\/10.1016\/j.vaccine.2012.05.035 PMID: 22643213","journal-title":"Vaccine"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1164\/rccm.201208-1385oc","volume":"188(4 )","author":"Cohen,J.","year":"2013","unstructured":"Cohen,J.; Hughes,E.; Day,C.; de Kock,M.; Geldenhuys,H.; Gelderbloem,S.; Hawkridge,A.; Hussey,G.; Ma-homed,H.; Makhethe, L. Induction and regulation of T cell immunity by the novel TB vaccine M72\/AS01 in South Af-rican adults. Am. J Respir. Crit. Care Med. 2013,188(4 ),492-502. https:\/\/dx.doi.org\/10.1164\/rccm.201208-1385oc PMID: 23306546","journal-title":"Am.J Respir.Crit.Care Med"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1803484","volume":"379(17)","author":"Van,Der,Meeren,O.;","year":"2018","unstructured":"Van Der Meeren,O.; Hatherill,M.; Nduba,V.; Wilkinson, R.J.; Muyoyeta,M.; Van Brakel,E.; Ayles, H.M.; Henos-troza,G.; Thienemann,F.; Scriba, T.J.; Diacon,A.; Blat-ner, G.L.; Demoiti\u00e9, M.A.; Tameris,M.; Malahleha,M.; Innes, J.C.; Hellstr\u00f6m,E.; Martinson,N.; Singh,T.; Akite, E.J.; Khatoon Azam,A.; Bollaerts,A.; Ginsberg, A.M.; Evans, T.G.; Gillard,P.; Tait, D.R. Phase 2b controlled trial of M72\/AS01E vaccine to prevent tuberculosis, N. Engl, J. Med. 2018,379(17),1621-1634. http:\/\/dx.doi.org\/10.1056\/NEJMoa1803484 PMID: 30280651","journal-title":"Engl, J.Med"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"e17.","DOI":"10.4110\/in.2018.18.e17","volume":"18(2)","author":"Kwon, B.E.","year":"2018","unstructured":"Kwon, B.E.; Ahn, J.H.; Min,S.; Kim,H.; Seo,J.; Yeo, S.G.; Ko, H.J. Development of new preventive and thera-peutic vaccines for tuberculosis. Immune Netw. 2018,18(2),e17. http:\/\/dx.doi.org\/10.4110\/in.2018.18.e17 PMID: 29732235","journal-title":"Immune Netw"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrmicro2048","volume":"7(1)","author":"Dye,C","year":"2009","unstructured":"Dye.; C. Doomsday postponed? Preventing and reversing epidemics of drug-resistant tuberculosis. Nat. Rev. Micro-biol. 2009,7(1),81-87. http:\/\/dx.doi.org\/10.1038\/nrmicro2048 PMID: 19079354","journal-title":"Nat.Rev.Micro-biol"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1093\/infdis\/jis425","volume":"207(8)","author":"Coler, R.N.","year":"2013","unstructured":"Coler, R.N.; Bertholet,S.; Pine, S.O.; Orr, M.T.; Reese,V.; Windish, H.P.; Davis,C.; Kahn,M.; Baldwin, S.L.; Reed, S.G. Therapeutic immunization against Mycobacterium tu-berculosis is an effective adjunct to antibiotic treatment, J. Infect. Dis. 2013,207(8),1242-1252. http:\/\/dx.doi.org\/10.1093\/infdis\/jis425 PMID: 22891286","journal-title":"Infect.Dis"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1007\/s40265-013-0081-8","volume":"73(10)","author":"Orme,I.M","year":"2013","unstructured":"Orme.; I.M. Vaccine development for tuberculosis: current progress. Drugs. 2013,73(10),1015-1024. http:\/\/dx.doi.org\/10.1007\/s40265-013-0081-8 PMID: 23794129","journal-title":"Drugs"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1172\/JCI46252","volume":"122(1)","author":"Lin, P.L.","year":"2012","unstructured":"Lin, P.L.; Dietrich,J.; Tan,E.; Abalos, R.M.; Burgos,J.; Bigbee,C.; Bigbee,M.; Milk,L.; Gideon, H.P.; Rodgers,M.; Cochran,C.; Guinn, K.M.; Sherman, D.R.; Klein,E.; Janssen,C.; Flynn, J.L.; Andersen, P. The multistage vac-cine H56 boosts the effects of BCG to protect Cynomolgus macaques against active tuberculosis and reactivation of la-tent Mycobacterium tuberculosis infection, J. Clin. Invest. 2012,122(1),303-314. http:\/\/dx.doi.org\/10.1172\/JCI46252 PMID: 22133873","journal-title":"Clin.Invest"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/nm.2285","volume":"17(2)","author":"Aagaard,C.","year":"2011","unstructured":"Aagaard,C.; Hoang,T.; Dietrich,J.; Cardona, P.J.; Izzo,A.; Dolganov,G.; Schoolnik, G.K.; Cassidy, J.P.; Bille-skov,R.; Andersen, P. A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat. Med. 2011,17(2),189-194. http:\/\/dx.doi.org\/10.1038\/nm.2285 PMID: 21258338","journal-title":"Nat.Med"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"4130","DOI":"10.1016\/j.vaccine.2015.06.051","volume":"33( 33)","author":"Luabeya, A.K.K.","year":"2015","unstructured":"Luabeya, A.K.K.; Kagina, B.M.; Tameris, M.D.; Geld-enhuys,H.; Hoff, S.T.; Shi,Z.; Kromann,I.; Hatherill,M.; Mahomed,H.; Hanekom, W.A.; Andersen,P.; Scriba, T.J.; Schoeman,E.; Krohn,C.; Day, C.L.; Africa,H.; Makhethe,L.; Smit,E.; Brown,Y.; Suliman,S.; Hughes, E.J.; Bang,P.; Snowden, M.A.; McClain,B.; Hussey, G.D. H56-032 Trial Study Group. First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults. Vac-cine. 2015,33( 33),4130-4140. http:\/\/dx.doi.org\/10.1016\/j.vaccine.2015.06.051 PMID: 26095509","journal-title":"Vac-cine"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/nrmicro2240","volume":"8(1)","author":"Draper, S.J.","year":"2010","unstructured":"Draper, S.J.; Heeney, J.L. Viruses as vaccine vectors for infectious diseases and cancer. Nat. Rev. Microbiol. 2010,8(1),62-73. http:\/\/dx.doi.org\/10.1038\/nrmicro2240 PMID: 19966816","journal-title":"Nat.Rev.Microbiol"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1164\/rccm.200910-1484OC","volume":"181(12)","author":"Abel,B.","year":"2010","unstructured":"Abel,B.; Tameris,M.; Mansoor,N.; Gelderbloem,S.; Hughes,J.; Abrahams,D.; Makhethe,L.; Erasmus,M.; de Kock,M.; van der Merwe,L.; Hawkridge,A.; Veldsman,A.; Hatherill,M.; Schirru,G.; Pau, M.G.; Hendriks,J.; Weverling, G.J.; Goudsmit,J.; Sizemore,D.; McClain, J.B.; Goetz,M.; Gearhart,J.; Mahomed,H.; Hussey, G.D.; Sadoff, J.C.; Hanekom, W.A. The novel tuberculosis vac-cine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults. Am, J. Respir. Crit. Care Med. 2010,181(12),1407-1417. http:\/\/dx.doi.org\/10.1164\/rccm.200910-1484OC PMID: 20167847","journal-title":"Am, J.Respir.Crit.Care Med"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1038\/nm1128","volume":"10(11)","author":"McShane,H.","year":"2004","unstructured":"McShane,H.; Pathan, A.A.; Sander, C.R.; Keating, S.M.; Gilbert, S.C.; Huygen,K.; Fletcher, H.A.; Hill, A.V. Re-combinant modified vaccinia virus ankara expressing anti-gen 85A boosts BCG-primed and naturally acquired an-timycobacterial immunity in humans. Nat. Med. 2004,10(11),1240-1244. http:\/\/dx.doi.org\/10.1038\/nm1128 PMID: 15502839","journal-title":"Nat.Med"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.4049\/jimm unol.171.3.1602","volume":"171(3)","author":"Goonetilleke, N.P.","year":"2003","unstructured":"Goonetilleke, N.P.; McShane,H.; Hannan, C.M.; Ander-son, R.J.; Brookes, R.H.; Hill, A.V. Enhanced immuno-genicity and protective efficacy against Mycobacterium tu-berculosis of bacille calmette-gu\u00e9rin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus ankara, J. Immunol. 2003,171(3),1602-1609. http:\/\/dx.doi.org\/10.4049\/jimm unol.171.3.1602 PMID: 12874255","journal-title":"Immunol"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.1002\/eji.200737504","volume":"37(11)","author":"Beveridge, N.E.","year":"2007","unstructured":"Beveridge, N.E.; Price, D.A.; Casazza, J.P.; Pathan, A.A.; Sander, C.R.; Asher, T.E.; Ambrozak, D.R.; Precopio, M.L.; Scheinberg,P.; Alder, N.C.; Roederer,M.; Koup, R.A.; Douek, D.C.; Hill, A.V.; McShane, H. Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations. Eur, J. Immunol. 2007,37(11),3089-3100. http:\/\/dx.doi.org\/10.1002\/eji.200737504 PMID: 17948267","journal-title":"Eur, J.Immunol"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"85","DOI":"10.18051\/UnivMed.2018.v37.85-87","volume":"37(2)","author":"Chondro,F","year":"2018","unstructured":"Chondro.; F. New tuberculosis vaccine to support tubercu-losis elimination. Universa Medicina. 2018,37(2),85-87. http:\/\/dx.doi.org\/10.18051\/UnivMed.2018.v37.85-87","journal-title":"Universa Medicina"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"4634","DOI":"10.1128\/IAI.00517-06","volume":"74(8)","author":"Santosuosso,M.","year":"2006","unstructured":"Santosuosso,M.; McCormick,S.; Zhang,X.; Zganiacz,A.; Xing, Z. Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Myco-bacterium bovis BCG immunization against pulmonary tu-berculosis. Infect. Immun. 2006,74(8),4634-4643. http:\/\/dx.doi.org\/10.1128\/IAI.00517-06 PMID: 16861651","journal-title":"Infect.Immun"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"205ra134.","DOI":"10.1126\/scitranslmed.3006843","volume":"5(205)","author":"Smaill,F.","year":"2013","unstructured":"Smaill,F.; Jeyanathan,M.; Smieja,M.; Medina, M.F.; Thanthrige-Don,N.; Zganiacz,A.; Yin,C.; Heriazon,A.; Damjanovic,D.; Puri,L.; Hamid,J.; Xie,F.; Foley,R.; Bramson,J.; Gauldie,J.; Xing, Z. A human type 5 adenovi-rus-based tuberculosis vaccine induces robust T cell re-sponses in humans despite preexisting anti-adenovirus im-munity. Sci. Transl. Med. 2013,5(205),205ra134. http:\/\/dx.doi.org\/10.1126\/scitranslmed.3006843 PMID: 24089406","journal-title":"Sci.Transl.Med"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/sji.12465","volume":"84( 4)","author":"M\u00e9ndez-Samperio.","year":"2016","unstructured":"M\u00e9ndez-Samperio.; P. Global efforts in the development of vaccines for tuberculosis: requirements for improved vac-cines against Mycobacterium tuberculosis Scand, J. Immu-nol. 2016,84( 4),204-210. http:\/\/dx.doi.org\/10.1111\/sji.12465 PMID: 27454335","journal-title":"Immu-nol"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1016\/j.vaccine.2016.02.079","volume":"34(26)","author":"Evans, T.G.","year":"2016","unstructured":"Evans, T.G.; Schrager,L.; Thole, J. Status of vaccine re-search and development of vaccines for tuberculosis. Vac-cine. 2016,34(26),2911-2914. http:\/\/dx.doi.org\/10.1016\/j.vaccine.2016.02.079 PMID: 26973073","journal-title":"Vac-cine"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"ftw016.","DOI":"10.1093\/femspd\/ftw016","volume":"74(4)","author":"Dockrell,H.M","year":"2016","unstructured":"Dockrell.; H.M. Towards new TB vaccines: what are the challenges? Pathog. Dis. 2016,74(4),ftw016. http:\/\/dx.doi.org\/10.1093\/femspd\/ftw016 PMID: 26960944","journal-title":"Dis"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ijbiomac.2018.08.037","volume":"120(Pt A)","author":"Khoshnood,S.","year":"2018","unstructured":"Khoshnood,S.; Heidary,M.; Haeili,M.; Drancourt,M.; Darban-Sarokhalil,D.; Nasiri, M.J.; Lohrasbi, V. Novel vaccine candidates against Mycobacterium tuberculosis Int, J. Biol. Macromol. 2018,120(Pt A),180-188. http:\/\/dx.doi.org\/10.1016\/j.ijbiomac.2018.08.037 PMID: 30098365","journal-title":"Biol.Macromol"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.prrv.2010.09.013","volume":"12(1)","author":"Hawkridge,T.","year":"2011","unstructured":"Hawkridge,T.; Mahomed, H. Prospects for a new, safer and more effective TB vaccine. Paediatr. Respir. Rev. 2011,12(1),46-51. http:\/\/dx.doi.org\/10.1016\/j.prrv.2010.09.013 PMID: 21172675","journal-title":"Paediatr.Respir.Rev"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.vaccine.2009.09.134","volume":"28(4)","author":"Vilaplana,C.","year":"2010","unstructured":"Vilaplana,C.; Montan\u00e9, E.; Pinto,S.; Barriocanal, A.M.; Domenech,G.; Torres,F.; Cardona, P.J.; Costa, J. Double-blind, randomized, placebo-controlled phase 1 clinical trial of the therapeutical antituberculous vaccine RUTI. Vac-cine. 2010,28(4),1106-1116. http:\/\/dx.doi.org\/10.1016\/j.vaccine.2009.09.134 PMID: 19853680","journal-title":"Vac-cine"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1046\/j.1440-1711.2001.01044.x","volume":"79(6)","author":"Sharma, A.K.","year":"2001","unstructured":"Sharma, A.K.; Khuller, G.K. DNA vaccines: future strate-gies and relevance to intracellular pathogens. Immunol. Cell Biol. 2001,79(6),537-546. http:\/\/dx.doi.org\/10.1046\/j.1440-1711.2001.01044.x PMID: 11903613","journal-title":"Immunol.Cell Biol"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1046\/j.1440-1711.2002.01087.x","volume":"80(4)","author":"Triccas, J.A.","year":"2002","unstructured":"Triccas, J.A.; Sun,L.; Palendira,U.; Britton, W.J. Com-parative effects of plasmid-encoded interleukin 12 and in-terleukin 18 on the protective efficacy of DNA vaccination against Mycobacterium tuberculosis Immunol. Cell Biol. 2002,80(4),346-350. http:\/\/dx.doi.org\/10.1046\/j.1440-1711.2002.01087.x PMID: 12121223","journal-title":"Cell Biol"},{"key":"ref=102","first-page":"285","volume":"43(3)","author":"Montgomery, D.L.","year":"1997","unstructured":"Montgomery, D.L.; Huygen,K.; Yawman, A.M.; Deck, R.R.; Dewitt, C.M.; Content,J.; Liu, M.A.; Ulmer, J.B. In-duction of humoral and cellular immune responses by vac-cination with M. tuberculosis antigen 85 DNA. Cell. Mol. Biol. 1997,43(3),285-292. PMID: 9193782","journal-title":"tuberculosis antigen 85 DNA.Cell..Mol.Biol"},{"key":"ref=103","doi-asserted-by":"publisher","author":"Kamath, A.T.","unstructured":"Kamath, A.T.; Hanke,T.; Briscoe,H.; Britton, W.J. Co-i mmunization with DNA vaccines expressing granulocyte-macrophage colony-stimulating factor and mycobacterial secreted proteins enhances T-cell immunity, but not protec-tive efficacy against Mycobacterium tuberculosis Immu-nology. 1999,96(4),511-516. http:\/\/dx.doi.org\/10.1046\/j.1365-2567.1999.00703.x PMID: 10233735","DOI":"10.1046\/j.1365-2567.1999.00703.x"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/gt.2008.13","volume":"15(9)","author":"Yu, D.H.","year":"2008","unstructured":"Yu, D.H.; Hu, X.D.; Cai, H. Efficient tuberculosis treat-ment in mice using chemotherapy and immunotherapy with the combined DNA vaccine encoding Ag85B, MPT-64 and MPT-83. Gene Ther. 2008,15(9),652-659. http:\/\/dx.doi.org\/10.1038\/gt.2008.13 PMID: 18288210","journal-title":"Gene Ther"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"1821.","DOI":"10.1038\/srep01821","volume":"3","author":"Chauhan,P.","year":"2013","unstructured":"Chauhan,P.; Jain,R.; Dey,B.; Tyagi, A.K. Adjunctive immunotherapy with a-crystallin based DNA vaccination reduces tuberculosis chemotherapy period in chronically infected mice. Sci. Rep. 2013,3,1821. http:\/\/dx.doi.org\/10.1038\/srep01821 PMID: 23660989","journal-title":"Sci.Rep"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"e21556.","DOI":"10.5812\/jjm.21556","volume":"8(8)","author":"Teimourpour,R.","year":"2015","unstructured":"Teimourpour,R.; Sadeghian,A.; Meshkat,Z.; Esmaelizad,M.; Sankian,M.; Jabbari, A-R. Construction of a DNA vaccine encoding Mtb32C and HBHA genes of Mycobacte-rium tuberculosis Jundishapur J. Microbiol. 2015,8(8),e21556. http:\/\/dx.doi.org\/10.5812\/jjm.21556 PMID: 26464766","journal-title":"Microbiol"},{"key":"ref=107","first-page":"1119","volume":"20(10)","author":"Teimourpour,R.","year":"2017","unstructured":"Teimourpour,R.; Peeridogaheh,H.; Teimourpour,A.; Ar-zanlou,M.; Meshkat, Z. A study on the immune response induced by a DNA v accine encoding Mtb32C-HBHA anti-gen of Mycobacterium tuberculosis. Iran, J. Basic Med. Sci. 2017,20(10),1119-1124. PMID: 29147487","journal-title":"Iran, J.Basic Med..Sci"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/gt.2011.140","volume":"19(5)","author":"Ahn, S.S.","year":"2012","unstructured":"Ahn, S.S.; Jeon, B.Y.; Kim, K.S.; Kwack, J.Y.; Lee, E.G.; Park, K.S.; Sung, Y.C.; Cho, S.N. Mtb32 is a promising tu-berculosis antigen for DNA vaccination in pre-and post-exposure mouse models. Gene Ther. 2012,19(5),570-575. http:\/\/dx.doi.org\/10.1038\/gt.2011.140 PMID: 21956689","journal-title":"Gene Ther"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0065-2660(05) 55002-8","volume":"55","author":"Liu, M.A.","year":"2005","unstructured":"Liu, M.A.; Ulmer, J.B. Human clinical trials of plasmid DNA vaccines. Adv. Genet. 2005,55,25-40. http:\/\/dx.doi.org\/10.1016\/S0065-2660(05) 55002-8 PMID: 16291211","journal-title":"Adv.Genet"},{"key":"ref=110","author":"Cardona,P-J","unstructured":"Cardona.; P-J. RUTI: a new chance to shorten the treatment of latent tuberculosis infection. Tuberculosis (Edinb.),2006,86(3-4),273-289. http:\/\/dx.doi.org\/10.1016\/j.tube.2006.01.024 PMID: 16545981.","journal-title":"Tuberculosis (Edinb.)"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"e89612.","DOI":"10.1371\/journal.pone.0089612","volume":"9(2)","author":"Nell, A.S.","year":"2014","unstructured":"Nell, A.S.; D\u2019lom,E.; Bouic,P.; Sabat\u00e9, M.; Bosser,R.; Picas,J.; Amat,M.; Churchyard,G.; Cardona, P.J. Safety, tolerability, and immunogenicity of the novel antitubercu-lous vaccine RUTI: randomized, placebo-controlled phase II clinical trial in patients with latent tuberculosis infection. PLoS One. 2014,9(2),e89612. http:\/\/dx.doi.org\/10.1371\/journal.pone.0089612 PMID: 24586912","journal-title":"PLoS One"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1046\/j.1365-2567.2001.01174.x","volume":"102(2)","author":"Skinner, M.A.","year":"2001","unstructured":"Skinner, M.A.; Prestidge,R.; Yuan,S.; Strabala, T.J.; Tan, P.L. The ability of heat-killed Mycobacterium vaccae to stimulate a cytotoxic T-cell response to an unrelated pro-tein is associated with a 65 kilodalton heat-shock protein. Immunology. 2001,102(2),225-233. http:\/\/dx.doi.org\/10.1046\/j.1365-2567.2001.01174.x PMID: 11260328","journal-title":"Immunology"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"3317","DOI":"10.1128\/IAI.65.8.3317-3327.1997","volume":"65(8)","author":"Hernandez-Pando,R.","year":"1997","unstructured":"Hernandez-Pando,R.; Pav\u00f6n,L.; Arriaga,K.; Orozco,H.; Madrid-Marina,V.; Rook, G. Pathogenesis of tuberculosis in mice exposed to low and high doses of an environmental mycobacterial saprophyte before infection. Infect. Immun. 1997,65(8),3317-3327. http:\/\/dx.doi.org\/10.1128\/IAI.65.8.3317-3327.1997 PMID: 9234793","journal-title":"Infect.Immun"},{"key":"ref=114","author":"Waddell, R.D.","unstructured":"Waddell, R.D.; Chintu,C.; Lein, A.D.; Zumla,A.; Karagas, M.R.; Baboo, K.S.; Habbema, J.D.F.; Tosteson, A.N.; Morin,P.; Tvaroha,S.; Arbeit, R.D.; Mwinga,A.; von Reyn, C.F. Safety and immunogenicity of a five-dose series of inactivated Mycobacterium vaccae vaccination for the prevention of HIV-associated tuberculosis. Clin. Infect. Dis. 2000,30( Suppl. 3),S309-S315. http:\/\/dx.doi.org\/10.1086\/313880 PMID: 10875806","journal-title":"Clin.Infect.Dis"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1097\/QAD.0b013e3283350f1b","volume":"24(5)","author":"von Reyn, C.F.","year":"2010","unstructured":"von Reyn, C.F.; Mtei,L.; Arbeit, R.D.; Waddell,R.; Cole,B.; Mackenzie,T.; Matee,M.; Bakari,M.; Tvaroha,S.; Adams, L.V.; Horsburgh, C.R.; Pallangyo, K. DarDar Study Group. Prevention of tuberculosis in bacille cal-mette-gu\u00e9rin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. AIDS. 2010,24(5),675-685. http:\/\/dx.doi.org\/ 10.1097\/QAD.0b013e3283350f1b PMID: 20118767","journal-title":"AIDS"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S0304-4165(99) 00167-1","volume":"1473(1)","author":"Dennis, J.W.","year":"1999","unstructured":"Dennis, J.W.; Granovsky,M.; Warren, C.E. Glycoprotein glycosylation and cancer progression. Biochim. Biophys. Acta. 1999,1473(1),21-34. http:\/\/dx.doi.org\/10.1016\/S0304-4165(99) 00167-1 PMID: 10580127","journal-title":"Biochim.Biophys.Acta"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2149\/tmh.2014-25","volume":"43(1)","author":"Kato,K.","year":"2015","unstructured":"Kato,K.; Ishiwa, A. The role of carbohydrates in infection strategies of enteric pathogens. Trop. Med. Health. 2015,43(1),41-52. http:\/\/dx.doi.org\/10.2149\/tmh.2014-25 PMID: 25859152","journal-title":"Trop.Med.Health"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1016\/j.carres.2003.07.008","volume":"338(23)","author":"Weintraub,A","year":"2003","unstructured":"Weintraub.; A. Immunology of bacterial polysaccharide antigens. Carbohydr. Res. 2003,338(23),2539-2547. http:\/\/dx.doi.org\/10.1016\/j.carres.2003.07.008 PMID: 14670715","journal-title":"Carbohydr.Res"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1586\/14760584.5.4.553","volume":"5 (4)","author":"Lockhart, S.P.","year":"2006","unstructured":"Lockhart, S.P.; Hackell, J.G.; Fritzell, B. Pneumococcal conjugate vaccines: emerging clinical information and its implications. Expert Rev. Vaccines. 2006,5 (4),553-564. http:\/\/dx.doi.org\/10.1586\/14760584.5.4.553 PMID: 16989635","journal-title":"Expert Rev.Vaccines"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/j.1365-2567.2004.01971.x","volume":"113(2)","author":"Kelly, D.F.","year":"2004","unstructured":"Kelly, D.F.; Moxon, E.R.; Pollard, A.J. Haemophilus influ-enzae type B conjugate vaccines. Immunology. 2004,113(2),163-174. http:\/\/dx.doi.org\/10.1111\/j.1365-2567.2004.01971.x PMID: 15379976","journal-title":"Immunology"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/bmb\/ldh021","volume":"70(1)","author":"Finn,A","year":"2004","unstructured":"Finn.; A. Bacterial polysaccharide-protein conjugate vac-cines. Br. Med. Bull. 2004,70(1),1-14. http:\/\/dx.doi.org\/10.1093\/bmb\/ldh021 PMID: 15339854","journal-title":"Br.Med.Bull"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"5513","DOI":"10.1016\/j.vaccine.2010.06.026","volume":"28(34)","author":"Dagan,R.","year":"2010","unstructured":"Dagan,R.; Poolman,J.; Siegrist, C.A. Glycoconjugate vaccines and immune interference: a review. Vaccine. 2010,28(34),5513-5523. http:\/\/dx.doi.org\/10.1016\/j.vaccine.2010.06.026 PMID: 20600514","journal-title":"Vaccine"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"5229","DOI":"10.1073\/pnas.1201964109","volume":"109(14)","author":"Malito,E.","year":"2012","unstructured":"Malito,E.; Bursulaya,B.; Chen,C.; Lo Surdo,P.; Picchi-anti,M.; Balducci,E.; Biancucci,M.; Brock,A.; Berti,F.; Bottomley, M.J.; Nissum,M.; Costantino,P.; Rappuo-li,R.; Spraggon, G. Structural basis for lack of toxicity of the diphtheria toxin mutant CRM197. Proc. Natl. Acad. Sci. US A. 2012,109(14),5229-5234. http:\/\/dx.doi.org\/10.1073\/pnas.1201964109 PMID: 22431623","journal-title":"Proc.Natl.Acad.Sci.US A"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/nchembio.2571","volume":"14(3)","author":"Angala, S.K.","year":"2018","unstructured":"Angala, S.K.; Palcekov\u00e1, Z.; Belardinelli, J.M.; Jackson, M. Covalent modifications of polysaccharides in mycobac-teria. Nat. Chem. Biol. 2018,14(3),193-198. http:\/\/dx.doi.org\/10.1038\/nchembio.2571 PMID: 29443974","journal-title":"Nat.Chem.Biol"},{"key":"ref=125","author":"Brennan,P.J","unstructured":"Brennan.; P.J. Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis Tuberculosis (Edinb.),2003,83(1-3),91-97. http:\/\/dx.doi.org\/10.1016\/S1472-9792(02) 00089-6 PMID: 12758196."},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1046\/j.1462-5822.2003.00351.x","volume":"6(2)","author":"Karakousis, P.C.","year":"2004","unstructured":"Karakousis, P.C.; Bishai, W.R.; Dorman, S.E. Mycobacte-rium tuberculosis cell envelope lipids and the host immune response. Cell. Microbiol. 2004,6(2),105-116. http:\/\/dx.doi.org\/10.1046\/j.1462-5822.2003.00351.x PMID: 14706097","journal-title":"Cell.Microbiol"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1111\/j.1365-2958.2004.04183.x","volume":"53(2)","author":"Briken,V.","year":"2004","unstructured":"Briken,V.; Porcelli, S.A.; Besra, G.S.; Kremer, L. Myco-bacterial lipoarabinomannan and related lipoglycans: from biogenesis to modulation of the immune response. Mol. Microbiol. 2004,53(2),391-403. http:\/\/dx.doi.org\/10.1111\/j.1365-2958.2004.04183.x PMID: 15228522","journal-title":"Mol.Microbiol"},{"key":"ref=128","doi-asserted-by":"crossref","first-page":"12345","DOI":"10.1016\/S0021-9258(18)67246-1","volume":"261(26)","author":"Hunter, S.W.","year":"1986","unstructured":"Hunter, S.W.; Gaylord,H.; Brennan, P.J. Structure and antigenicity of the phosphorylated lipopolysaccharide anti-gens from the leprosy and tubercle bacilli, J. Biol. Chem. 1986,261(26),12345-12351. PMID: 3091602","journal-title":"Biol.Chem"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1111\/j.1574-6976.2011.00276.x","volume":"35(6)","author":"Mishra, A.K.","year":"2011","unstructured":"Mishra, A.K.; Driessen, N.N.; Appelmelk, B.J.; Besra, G.S. Lipoarabinomannan and related glycoconjugates: structure, biogenesis and role in Mycobacterium tuberculosis physi-ology and host-pathogen interaction. FEMS Microbiol. Rev. 2011,35(6),1126-1157. http:\/\/dx.doi.org\/10.1111\/j.1574-6976.2011.00276.x PMID: 21521247","journal-title":"FEMS Microbiol.Rev"},{"key":"ref=130","first-page":"240","volume":"76(2)","author":"Moreno,C.","year":"1989","unstructured":"Moreno,C.; Taverne,J.; Mehlert,A.; Bate, C.A.; Brealey, R.J.; Meager,A.; Rook, G.A.; Playfair, J.H. Lipoarabino-mannan from Mycobacterium tuberculosis induces the pro-duction of tumour necrosis factor from human and murine macrophages. Clin. Exp. Immunol. 1989,76(2),240-245. PMID: 2503277","journal-title":"Clin.Exp..Immunol"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"8071","DOI":"10.1021\/jo061233x","volume":"71(21)","author":"Hlemann,A.","year":"2006","unstructured":"H\u00f6lemann,A.; Stocker, B.L.; Seeberger, P.H. Synthesis of a core arabinomannan oligosaccharide of Mycobacterium tuberculosis J. Org. Chem. 2006,71(21),8071-8088. http:\/\/dx.doi.org\/10.1021\/jo061233x PMID: 17025296","journal-title":"Org.Chem"},{"key":"ref=132","first-page":"11","volume":"85(1)","author":"Fietta,A.","year":"2000","unstructured":"Fietta,A.; Francioli,C.; Gialdroni Grassi, G. Mycobacterial lipoarabinomannan affects human polymorphonuclear and mononuclear phagocyte functions differently. Haema-tologica. 2000,85(1),11-18. PMID: 10629585","journal-title":"Haema-tologica"},{"key":"ref=133","first-page":"3028","volume":"138(9)","author":"Kaplan,G.","year":"1987","unstructured":"Kaplan,G.; Gandhi, R.R.; Weinstein, D.E.; Levis, W.R.; Patarroyo, M.E.; Brennan, P.J.; Cohn, Z.A. Mycobacterium leprae antigen-induced suppression of T cell proliferation in vitro, J. Immunol. 1987,138(9),3028-3034. PMID: 3106496","journal-title":"Immunol"},{"key":"ref=134","first-page":"206","volume":"74(2)","author":"Moreno,C.","year":"1988","unstructured":"Moreno,C.; Mehlert,A.; Lamb, J. The inhibitory effects of mycobacterial lipoarabinomannan and polysaccharides upon polyclonal and monoclonal human T cell prolifera-tion. Clin. Exp. Immunol. 1988,74(2),206-210. PMID: 3147152","journal-title":"Clin.Exp..Immunol"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1128\/IAI.59.5.1755-1761.1991","volume":"59(5)","author":"Chan,J.","year":"1991","unstructured":"Chan,J.; Fan, X.D.; Hunter, S.W.; Brennan, P.J.; Bloom, B.R. Lipoarabinomannan, a possible virulence factor in-volved in persistence of Mycobacterium tuberculosis within macrophages. Infect. Immun. 1991,59(5),1755-1761. http:\/\/dx.doi.org\/10.1128\/IAI.59.5.1755-1761.1991 PMID: 1850379","journal-title":"Infect.Immun"},{"key":"ref=136","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.60.4.1441-1446.1992","author":"Barnes, P.F.","unstructured":"Barnes, P.F.; Chatterjee,D.; Brennan, P.J.; Rea, T.H.; Modlin, R.L. Tumor necrosis factor production in patients with leprosy. Infect. Immun. 1992,60(4),1441-1446. http:\/\/dx.doi.org\/10.1128\/IAI.60.4.1441-1446.1992 PMID: 1548069 [ 137] Minion,J.; Leung,E.; Talbot,E.; Dheda,K.; Pai,M.; Men-zies, D. Diagnosing tuberculosis with urine lipoarabino-mannan: systematic review and meta-analysis. Eur. Respir, J. 2011,38(6),1398-1405. http:\/\/dx.doi.org\/10.1183\/09031936.00025711 PMID: 21700601","journal-title":"Infect.Immun"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1016\/S0264-410X(99) 00124-3","volume":"17(22)","author":"Hamasur,B.","year":"1999","unstructured":"Hamasur,B.; K\u00e4llenius,G.; Svenson, S.B. Synthesis and immunologic characterisation of Mycobacterium tubercu-losis lipoarabinomannan specific oligosaccharide-protein conjugates. Vaccine. 1999,17(22),2853-2861. http:\/\/dx.doi.org\/10.1016\/S0264-410X(99) 00124-3 PMID: 10438056","journal-title":"Vaccine"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"4081","DOI":"10.1016\/S0264-410X(03) 00274-3","volume":"21(25-26)","author":"Hamasur,B.","year":"2003","unstructured":"Hamasur,B.; Haile,M.; Pawlowski,A.; Schr\u00f6der,U.; Wil-liams,A.; Hatch,G.; Hall,G.; Marsh,P.; K\u00e4llenius,G.; Svenson, S.B. Mycobacterium tuberculosis arabinoman-nan-protein conjugates protect against tuberculosis. Vac-cine. 2003,21(25-26),4081-4093. http:\/\/dx.doi.org\/10.1016\/S0264-410X(03) 00274-3 PMID: 12922145","journal-title":"Vac-cine"},{"key":"ref=140","author":"Haile,M.","unstructured":"Haile,M.; Hamasur,B.; Jaxmar,T.; Gavier-Widen,D.; Chambers, M.A.; Sanchez,B.; Schr\u00f6der,U.; K\u00e4llenius,G.; Svenson, S.B.; Pawlowski, A. Nasal boost with adjuvanted heat-killed BCG or arabinomannan-protein conjugate im-proves primary BCG-induced protection in C57BL\/6 mice. Tuberculosis (Edinb.),2005,85(1-2),107-114. http:\/\/dx.doi.org\/10.1016\/j.tube.2004.09.013 PMID: 15687034"},{"key":"ref=141","author":"Kallert,S.","unstructured":"Kallert,S.; Zenk, S.F.; Walther,P.; Grieshober,M.; Weil,T.; Stenger, S. Liposomal delivery of lipoarabinomannan triggers Mycobacterium tuberculosis specific T-cells. Tu-berculosis (Edinb.),2015,95(4),452-462. http:\/\/dx.doi.org\/10.1016\/j.tube.2015.04.001 PMID: 26043674","journal-title":"Tu-berculosis (Edinb.)"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1128\/JCM.42.7.3225-3231.2004","volume":"42(7)","author":"Glatman-Freedman,A.","year":"2004","unstructured":"Glatman-Freedman,A.; Casadevall,A.; Dai,Z.; Jacobs, W.R. Jr; Li,A.; Morris, S.L.; Navoa, J.A.D.; Piperdi,S.; Robbins, J.B.; Schneerson,R.; Schwebach, J.R.; Shapiro, M. Antigenic evidence of prevalence and diversity of My-cobacterium tuberculosis arabinomannan, J. Clin. Micro-biol. 2004,42(7),3225-3231. http:\/\/dx.doi.org\/10.1128\/JCM.42.7.3225-3231.2004 PMID: 15243086","journal-title":"J.Clin.Micro-biol"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"e1006250.","DOI":"10.1371\/journal.ppat.1006250","volume":"13(3)","author":"Prados-Rosales,R.","year":"2017","unstructured":"Prados-Rosales,R.; Carre\u00f1o,L.; Cheng,T.; Blanc,C.; Weinrick,B.; Malek,A.; Lowary, T.L.; Baena,A.; Joe,M.; Bai,Y.; Kalscheuer,R.; Batista-Gonzalez,A.; Saavedra, N.A.; Sampedro,L.; Tom\u00e1s,J.; Anguita,J.; Hung, S.C.; Tripathi,A.; Xu,J.; Glatman-Freedman,A.; Jacobs, W.R. Jr; Chan,J.; Porcelli, S.A.; Achkar, J.M.; Casadevall, A. Enhanced control of Mycobacterium tuberculosis ex-trapulmonary dissemination in mice by an arabinomannan-protein conjugate vaccine. PLoS Pathog. 2017,13(3),e1006250. http:\/\/dx.doi.org\/10.1371\/journal.ppat.1006250 PMID: 28278283","journal-title":"PLoS Pathog"},{"key":"ref=144","author":"M cIntosh, J.D.","unstructured":"M cIntosh, J.D.; Brimble, M.A.; Brooks, A.E.S.; Dunbar, P.R.; Kowalczyk,R.; Tomabechi,Y.; Fairbanks, A.J. Con-vergent chemo-enzymatic synthesis of mannosylated gly-copeptides; targeting of putative vaccine candidates to anti-gen presenting cells. Chem. Sci. (Camb.),2015,6(8),4636-4642. http:\/\/dx.doi.org\/10.1039\/C5SC00952A PMID: 28717478","journal-title":"Chem.Sci.(Camb.)"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"1081.","DOI":"10.3390\/molecules22071081","volume":"22(7)","author":"Bavaro,T.","year":"2017","unstructured":"Bavaro,T.; Tengattini,S.; Piubelli,L.; Mangione,F.; Ber-nardini,R.; Monzillo,V.; Calarota,S.; Marone,P.; Ami-cosante,M.; Pollegioni,L.; Temporini,C.; Terreni, M. Glycosylation of recombinant antigenic proteins from My-cobacterium tuberculosis : in silico prediction of protein epitopes and ex vivo biological evaluation of new semi-synthetic glycoconjugates. Molecules. 2017,22(7),1081. http:\/\/dx.doi.org\/10.3390\/molecules22071081 PMID: 28661444","journal-title":"Molecules"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"23171","DOI":"10.1039\/C8RA03535K","volume":"8(41)","author":"Rinaldi,F.","year":"2018","unstructured":"Rinaldi,F.; Tengattini,S.; Piubelli,L.; Bernardini,R.; Mangione,F.; Bavaro,T.; Paone,G.; Mattei,M.; Polle-gioni,L.; Filice, G. Rational design, preparation and char-acterization of recombinant Ag85B variants and their gly-coconjugates with T-cell antigenic activity against Myco-bacterium tuberculosis RSC. Adv. 2018,8(41),23171-23180. http:\/\/dx.doi.org\/10.1039\/C8RA03535K","journal-title":"Adv"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1016\/j.febslet.2006.03.053","volume":"580(12)","author":"Vliegenthart,J.F","year":"2006","unstructured":"Vliegenthart.; J.F. Carbohydrate based vaccines. FEBS Lett. 2006,580(12),2945-2950. http:\/\/dx.doi.org\/10.1016\/j.febslet.2006.03.053 PMID: 16630616","journal-title":"FEBS Lett"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nchem.399","volume":"1(8)","author":"Boltje, T.J.","year":"2009","unstructured":"Boltje, T.J.; Buskas,T.; Boons, G.J. Opportunities and challenges in synthetic oligosaccharide and glycoconjugate research. Nat. Chem. 2009,1(8),611-622. http:\/\/dx.doi.org\/10.1038\/nchem.399 PMID: 20161474","journal-title":"Nat.Chem"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1021\/ol4036903","volume":"16(3)","author":"Gao,J.","year":"2014","unstructured":"Gao,J.; Liao,G.; Wang,L.; Guo, Z. Synthesis of a minia-ture lipoarabinomannan. Org. Lett. 2014,16(3),988-991. http:\/\/dx.doi.org\/10.1021\/ol4036903 PMID: 24444032","journal-title":"Org.Lett"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1021\/ja109932t","volume":"133(7)","author":"Ishiwata,A.","year":"2011","unstructured":"Ishiwata,A.; Ito, Y. Synthesis of docosasaccharide arabi-nan motif of mycobacterial cell wall, J. Am. Chem. Soc. 2011,133(7),2275-2291. http:\/\/dx.doi.org\/10.1021\/ja109932t PMID: 21287985","journal-title":"Am.Chem.Soc"},{"key":"ref=151","author":"Kandasamy,J.","unstructured":"Kandasamy,J.; Hurevich,M.; Seeberger, P.H. Automated solid phase synthesis of oligoarabinofuranosides. Chem. Commun. (Camb.),2013,49(40),4453-4455. http:\/\/dx.doi.org\/10.1039\/c3cc00042g PMID: 23370381"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"5525","DOI":"10.1021\/ol062198j","volume":"8(24)","author":"Ishiwata,A.","year":"2006","unstructured":"Ishiwata,A.; Akao,H.; Ito, Y. Stereoselective synthesis of a fragment of mycobacterial arabinan. Org. Lett. 2006,8(24),5525-5528. http:\/\/dx.doi.org\/10.1021\/ol062198j PMID: 17107063","journal-title":"Org.Lett"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1021\/bc400486w","volume":"25(4)","author":"Bundle, D.R.","year":"2014","unstructured":"Bundle, D.R.; Tam, P-H.; Tran, H-A.; Paszkiewicz,E.; Cartmell,J.; Sadowska, J.M.; Sarkar,S.; Joe,M.; Kitov, P.I. Oligosaccharides and peptide displayed on an am-phiphilic polymer enable solid phase assay of hapten spe-cific antibodies. Bioconjug. Chem. 2014,25(4),685-697. http:\/\/dx.doi.org\/10.1021\/bc400486w PMID: 24601638","journal-title":"Bioconjug.Chem"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"12085","DOI":"10.1021\/acs.joc.7b01817","volume":"82(23)","author":"Wang,L.","year":"2017","unstructured":"Wang,L.; Feng,S.; Wang,S.; Li,H.; Guo,Z.; Gu, G. Syn-thesis and immunological comparison of differently linked lipoarabinomannan oligosaccharide-monophosphoryl lipid A conjugates as antituberculosis vaccines, J. Org. Chem. 2017,82(23),12085-12096. http:\/\/dx.doi.org\/10.1021\/acs.joc.7b01817 PMID: 29112822","journal-title":"Org.Chem"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"3238","DOI":"10.1039\/C4OB00390J","volume":"12(20)","author":"Zhou,Z.","year":"2014","unstructured":"Zhou,Z.; Mondal,M.; Liao,G.; Guo, Z. Synthesis and evaluation of monophosphoryl lipid A derivatives as fully synthetic self-adjuvanting glycoconjugate cancer vaccine carriers. Org. Biomol. Chem. 2014,12(20),3238-3245. http:\/\/dx.doi.org\/10.1039\/C4OB00390J PMID: 24728423","journal-title":"Org.Biomol.Chem"},{"key":"ref=156","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.carbpol.2017.07.045","volume":"175","author":"Wattanasiri,C.","year":"2017","unstructured":"Wattanasiri,C.; Paha,J.; Ponpuak,M.; Ruchirawat,S.; Boonyarattanakalin, S. Synthesis of synthetic mannan backbone polysaccharides found on the surface of Myco-bacterium tuberculosis as a vaccine adjuvant and their im-munological properties. Carbohydr. Polym. 2017,175,746-755. ht tp:\/\/dx.doi.org\/10.1016\/j.carbpol.2017.07.045 PMID: 28917925","journal-title":"Carbohydr.Polym"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/167726","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/167726\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/167726","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,20]],"date-time":"2021-02-20T16:23:10Z","timestamp":1613838190000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/167726\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,11]]},"references-count":154,"journal-issue":{"issue":"31","published-print":{"date-parts":[[2020,9,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867326666181126112124","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-10-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-08","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}